Continuing Medical Education

CME/CE

Use the tool below to view all available Medtelligence Series

- Robert J. Chilton, DO
  Peer
- John R. Nelson, MD, FACC, FNLA, FASNC
  Peer
1
CME/CE
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
1.00 credits
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
1.00 credits
- Ileana L. Piña, MD, MPH, FAHA, FACC
  Peer
- Javed Butler, MD, MBA, MPH
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
1
CME/CE
From Guidelines to Practice: Key Updates From 2021 HFSA
From Guidelines to Practice: Key Updates From 2021 HFSA
0.25 credits
From Guidelines to Practice: Key Updates From 2021 HFSA
0.25 credits
- Ileana L. Piña, MD, MPH, FAHA, FACC
  Peer
- Javed Butler, MD, MBA, MPH
  Peer
- Gregg C. Fonarow, MD
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
2
CME/CE
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities to Improve Patient Outcomes
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities to Improve Patient Outcomes
1.50 credits
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities...
1.50 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  Peer
5
CME/CE
A New Normal? COVID-19 and HF in Clinical Trials
A New Normal? COVID-19 and HF in Clinical Trials
0.25 credits
A New Normal? COVID-19 and HF in Clinical Trials
0.25 credits
- George L. Bakris, MD
  Peer
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
  Peer
- Bertram Pit, MD
  Peer
8
CME/CE
FIGARO-DKD and FIDELITY Analysis: Key Takeaways
FIGARO-DKD and FIDELITY Analysis: Key Takeaways
0.25 credits
FIGARO-DKD and FIDELITY Analysis: Key Takeaways
0.25 credits
- George L. Bakris, MD
  Peer
- Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
  Peer
- Robert Toto, MD
  Peer
3
CME/CE
Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always the Goal
Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always the Goal
0.25 credits
Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Alwa...
0.25 credits
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
  Peer
- Leslie Cho, MD
  Peer
6
CME/CE
Clinician’s Update on Omega-3s in ASCVD Risk Reduction
Clinician’s Update on Omega-3s in ASCVD Risk Reduction
0.25 credits
Clinician’s Update on Omega-3s in ASCVD Risk Reduction
0.25 credits
- Lawrence A. Leiter, MD
  Peer
- Peter Libby, MD
  Peer
- Christie M. Ballantyne, MD
  Peer
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  Peer
- R. Preston Mason, PhD
  Peer
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
  Peer
- Prof. Kausik Ray, MBChB, MD, MPhil
  Peer
2
CME/CE Meeting
CME/CE Meeting
Clinical Rundown: 3 Hot Topic Session...
November 14, 2021
07:30 PM - 09:00 PM EST
1.50 creditsLearn more
- Ileana L. Piña, MD, MPH, FAHA, FACC
  Peer
- Javed Butler, MD, MBA, MPH
  Peer
4
CME/CE
Potassium Binders Facilitate Continued RAASi Therapy: Helpful Tips for Clinicians
Potassium Binders Facilitate Continued RAASi Therapy: Helpful Tips for Clinicians
0.25 credits
Potassium Binders Facilitate Continued RAASi Therapy: Helpful Tips for Clinic...
0.25 credits
- Michael Miller, MD, FACC, FAHA, FNLA
  Peer
- Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC
  Peer
16
CME/CE
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Acid Clinical Trials and EPA/DHA
0.25 credits
Understanding the Differences Between STRENGTH and REDUCE-IT Omega-3 Fatty Ac...
0.25 credits
- Matthew R. Weir, MD
  Peer
- Gates B. Colbert, MD
  Peer
- Robert Toto, MD
  Peer
14
CME/CE
Expert Insights: Managing Patients with CKD, Hyperkalemia, and Continued RAASi Therapy Through a Case Study Approach
Expert Insights: Managing Patients with CKD, Hyperkalemia, and Continued RAASi Therapy Through a Case Study Approach
0.25 credits
Expert Insights: Managing Patients with CKD, Hyperkalemia, and Continued RAAS...
0.25 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Paul W. Armstrong, MD
  Peer
16
CME/CE
New Therapies Offer Improved Outcomes in HFrEF Management
New Therapies Offer Improved Outcomes in HFrEF Management
0.25 credits
New Therapies Offer Improved Outcomes in HFrEF Management
0.25 credits
- Eliot Brinton, MD, FAHA, FNLA
  Peer
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
  Peer
23
CME/CE Broadcast Replay
CME/CE Broadcast Replay
The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue
The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue
0.75 credits
The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert D...
0.75 credits
- Eliot Brinton, MD, FAHA, FNLA
  Peer
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
  Peer
11
CME/CE
0.25 credits
Prevention of ASCVD in Women Through Lipid Management in the New Era
0.25 credits
- James A. Underberg, MD
  Peer
2
CME/CE
Update on ASCVD Risk Assessment and Management
Update on ASCVD Risk Assessment and Management
1.00 credits
Update on ASCVD Risk Assessment and Management
1.00 credits
- Leonard H. Calabrese, DO
  Peer
- John R. Tesser, MD
  Peer
2
CME/CE
Pinpointing the Top Questions about Biosimilars in Rheumatology
Pinpointing the Top Questions about Biosimilars in Rheumatology
Pinpointing the Top Questions about Biosimilars in Rheumatology

Popular

CME/CE

CME/CE

CME/CE

CME/CE

CME/CE

CME/CE

CME/CE

CME/CE Meeting

CME/CE

CME/CE

CME/CE

CME/CE

CME/CE Broadcast Replay

CME/CE

CME/CE

CME/CE

NEED HELP?

Contact us

NEED HELP?

Contact us

Popular

CME/CE

CME/CE

CME/CE

CME/CE

CME/CE

CME/CE

CME/CE

CME/CE Meeting

CME/CE

CME/CE

CME/CE

CME/CE

CME/CE Broadcast Replay

CME/CE

CME/CE

CME/CE

Title

NEED HELP?

Contact us

Share on ReachMD

Get a Dose of Medtelligence in Your Inbox and Practice Smarter Medicine